Screener
Oruka Therapeutics, Inc. ORKA Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055769
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(31,820) | $(20,999) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 6,968 | 4,883 |
| Net accretion of premiums and discounts on marketable securities | (446) | (1,797) |
| Non-cash lease expense | 143 | 62 |
| Depreciation expense | 43 | 16 |
| Changes in operating assets and liabilities: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Oruka Therapeutics, Inc.'s stock-based comp?
- Oruka Therapeutics, Inc. (ORKA) reported stock-based comp of $6.97M in Q1 2026.
- How has Oruka Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Oruka Therapeutics, Inc.'s stock-based comp increased by 42.7% year-over-year, from $4.88M to $6.97M.
- What is the long-term trend for Oruka Therapeutics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Oruka Therapeutics, Inc.'s stock-based comp has grown at a 164.3% compound annual growth rate (CAGR), from $497K to $24.24M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Oruka Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude